To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback